Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participants and Target Disease Characteristics- -
•Confirmed disease progression by RECIST 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab
•Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.
•Age and Reproduction Sexually active males with WOCBP must agree to instructions for contraception and fetal protection.
•WOCBP need to use contraception throughout the study and for 5 months post treatment.

•Active central nervous system metastases
•Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.
•Any major surgery 28 days before 1st treatment Concomitant Therapy
•participants that have received a live vaccine within 30 days of treatment.
•use of investigational agent or device with in 28 days before first dosage study treatment.
•Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction

Related studies

NCT07227402 · Renal Cell Carcinoma

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

NCT04693377 · Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, and more

NCT07117227 · Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), and more

NCT05969496 · Renal Cancer, Kidney Cancer, and more

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma